NO20081476L - Substituerte benzimidazoler og fremgangsmater for fremstilling - Google Patents

Substituerte benzimidazoler og fremgangsmater for fremstilling

Info

Publication number
NO20081476L
NO20081476L NO20081476A NO20081476A NO20081476L NO 20081476 L NO20081476 L NO 20081476L NO 20081476 A NO20081476 A NO 20081476A NO 20081476 A NO20081476 A NO 20081476A NO 20081476 L NO20081476 L NO 20081476L
Authority
NO
Norway
Prior art keywords
preparation
methods
substituted benzimidazoles
formula
benzimidazoles
Prior art date
Application number
NO20081476A
Other languages
English (en)
Norwegian (no)
Inventor
Martin Dimitroff
Bridget R Miller
Brady S Stillwell
David A Siesel
Tyson Swiftney
Brian Diaz
Danlin Gu
Jonathan P Van Dyck
David Ryckman
Daniel J Poon
Teresa E Pick
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20081476L publication Critical patent/NO20081476L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20081476A 2005-08-30 2008-03-26 Substituerte benzimidazoler og fremgangsmater for fremstilling NO20081476L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71253905P 2005-08-30 2005-08-30
US71310805P 2005-08-30 2005-08-30
US73159105P 2005-10-27 2005-10-27
US77468406P 2006-02-17 2006-02-17
PCT/US2006/034112 WO2007027950A1 (en) 2005-08-30 2006-08-30 Substituted benzimidazoles and methods of preparation

Publications (1)

Publication Number Publication Date
NO20081476L true NO20081476L (no) 2008-03-26

Family

ID=37434025

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081476A NO20081476L (no) 2005-08-30 2008-03-26 Substituerte benzimidazoler og fremgangsmater for fremstilling

Country Status (37)

Country Link
US (6) US7482367B2 (el)
EP (2) EP1926722B1 (el)
JP (4) JP5210867B2 (el)
KR (2) KR20080039965A (el)
AR (2) AR055622A1 (el)
AT (2) ATE526325T1 (el)
AU (2) AU2006287688B2 (el)
BR (2) BRPI0615314A2 (el)
CA (2) CA2620472C (el)
CR (1) CR9716A (el)
CU (1) CU23784B7 (el)
CY (2) CY1111871T1 (el)
DE (1) DE602006021036D1 (el)
DK (2) DK1926722T3 (el)
EA (1) EA014230B1 (el)
EC (2) ECSP088210A (el)
ES (1) ES2374451T3 (el)
GE (1) GEP20105004B (el)
GT (1) GT200600394A (el)
HK (2) HK1117519A1 (el)
HN (1) HN2008000317A (el)
HR (2) HRP20110312T1 (el)
IL (2) IL189080A (el)
MA (2) MA29915B1 (el)
MY (2) MY148694A (el)
NI (1) NI200800060A (el)
NO (1) NO20081476L (el)
NZ (2) NZ565450A (el)
PE (2) PE20070335A1 (el)
PL (2) PL1926722T3 (el)
PT (2) PT1924577E (el)
RS (1) RS52099B (el)
SI (2) SI1926722T1 (el)
SM (1) SMAP200800022A (el)
TN (2) TNSN08088A1 (el)
TW (2) TW200804345A (el)
WO (2) WO2007030377A1 (el)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
GB0609378D0 (en) * 2006-05-11 2006-06-21 Novartis Ag Organic compounds
PL2046292T3 (pl) * 2006-07-21 2010-08-31 Novartis Ag Preparaty eterów benzymidazolilo-pirydylowych
PE20080766A1 (es) 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
RU2009114745A (ru) * 2006-09-19 2010-10-27 Новартис АГ (CH) Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования
MY148438A (en) * 2007-03-02 2013-04-30 Novartis Ag Solid forms of a raf kinase inhibitor
CN101674828A (zh) * 2007-05-23 2010-03-17 诺瓦提斯公司 用于治疗甲状腺癌的Raf抑制剂
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
WO2009028629A1 (ja) * 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
AU2009257487B2 (en) * 2008-06-13 2013-01-31 Novartis Ag Substituted benzimidazoles for neurofibromatosis
BRPI0915901A2 (pt) * 2008-07-11 2015-10-27 Novartis Ag combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um modulador da via ras/raf/mek
MX2011004505A (es) * 2008-10-29 2011-05-31 Merck Sharp & Dohme Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos.
WO2010064611A1 (ja) 2008-12-01 2010-06-10 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2011020936A (ja) * 2009-07-14 2011-02-03 Lotte Co Ltd 口臭除去剤
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
WO2011044072A1 (en) 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
KR20130116291A (ko) * 2010-11-19 2013-10-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Braf 억제제를 이용한 치료 방법
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
JP6058009B2 (ja) 2011-08-31 2017-01-11 ノバルティス アーゲー Ｐｉ３ｋ−およびｍｅｋ−阻害剤の相乗的な組合せ
RU2641693C2 (ru) * 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
CN103917236A (zh) 2011-11-11 2014-07-09 诺华股份有限公司 治疗增生性疾病的方法
LT2782557T (lt) 2011-11-23 2018-12-27 Array Biopharma, Inc. Farmacinės kompozicijos
PL2855448T3 (pl) 2012-05-15 2017-09-29 Cancer Research Technology Ltd 5-[[4-[[morfolino-2-ilo]metyloamino]-5-(trifluorometylo)-2-pirydylo]amino]pirazyno-2-karbonitryl i jego zastosowanie terapeutyczne
BR112015010477A2 (pt) 2012-11-08 2017-07-11 Novartis Ag combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
CN105209073A (zh) 2013-03-21 2015-12-30 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
US9890187B2 (en) 2015-06-26 2018-02-13 Epos-Iasis Research And Development, Ltd. Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
WO2017001625A1 (en) 2015-06-30 2017-01-05 Sequessome Technology Holdings Limited Multiphasic compositions
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
JP2019500893A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
CN105481944B (zh) * 2015-12-10 2019-01-08 华南农业大学 一种苯并咪唑衍生物二肽铜配合物及其制备方法和应用
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
JP7094942B2 (ja) * 2017-03-15 2022-07-04 住友ファーマ株式会社 ベンズイミダゾール誘導体の製造方法
DK3612519T3 (da) 2017-04-18 2022-03-07 Lilly Co Eli Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
JP7416716B2 (ja) 2017-12-28 2024-01-17 トラクト ファーマシューティカルズ インコーポレイテッド 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3876930A4 (en) * 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND THEIR USES
BR112021013637A2 (pt) 2019-01-11 2021-09-14 Naegis Pharmaceuticals Inc. Inibidores da síntese de leucotrieno
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894037A (en) * 1971-05-24 1975-07-08 Ciba Geigy Corp Certain isothiocyanobenzimidazoles
CH634306A5 (de) * 1977-04-12 1983-01-31 Ciba Geigy Ag Benzimidazolderivate, verfahren zu ihrer herstellung und anthelmintische mittel enthaltend diese verbindungen als wirkstoffe.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4294926A (en) * 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
US4430502A (en) * 1982-08-13 1984-02-07 The Upjohn Company Pyridinyl substituted benzimidazoles and quinoxalines
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) * 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
GB8307865D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4782084A (en) * 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5290946A (en) * 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US5118853A (en) * 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US4929437A (en) * 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5189164A (en) * 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JPH06759B2 (ja) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5420245A (en) * 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5041453A (en) * 1990-05-30 1991-08-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4
FR2677020B1 (fr) * 1991-05-31 1993-08-27 Cird Galderma Composes derives de benzimidazole, leur procede de preparation et leur utilisation dans les domaines therapeutique et cosmetique.
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
CA2111902A1 (en) 1992-12-21 1994-06-22 Jack Beuford Campbell Antitumor compositions and methods of treatment
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
WO1994026723A2 (en) * 1993-05-14 1994-11-24 Genentech, Inc. ras FARNESYL TRANSFERASE INHIBITORS
US5602098A (en) * 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5661152A (en) * 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
AU1615895A (en) 1994-03-31 1995-10-12 Bristol-Myers Squibb Company Imidazole-containing inhibitors of farnesyl protein transferase
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5510510A (en) * 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US6358932B1 (en) * 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) * 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
EP0701907A1 (en) 1994-09-13 1996-03-20 Agfa-Gevaert N.V. A dye donor element for use in a thermal dye transfer process
US6037136A (en) * 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
ATE218556T1 (de) * 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
WO1997024334A1 (fr) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Derives du benzimidazole
GB9602029D0 (en) * 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
IL127210A0 (en) * 1996-05-23 1999-09-22 Applied Research Systems Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
FR2751649B1 (fr) * 1996-07-26 1998-08-28 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE69734362T2 (de) * 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6127380A (en) * 1997-02-18 2000-10-03 American Home Products Corporation 4-aminoalkoxy-1H-benzoimidazoles
WO1998040381A1 (en) * 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US5932600A (en) * 1997-03-14 1999-08-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
WO1999001128A1 (en) * 1997-07-03 1999-01-14 Neurogen Corporation Certain diarylimidazole derivatives; a new class of npy specific ligands
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
FR2766822B1 (fr) * 1997-07-30 2001-02-23 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) * 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
AU760527C (en) * 1998-05-22 2004-05-06 Smithkline Beecham Corporation Novel 2-alkyl substituted imidazole compounds
US6420555B1 (en) * 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
FR2780973B1 (fr) * 1998-07-09 2001-10-05 Hoechst Marion Roussel Inc Procede de preparation du 4-(3-pyridinyl)-1h-imidazole, et les intermediaires mis en oeuvre
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
US6211177B1 (en) * 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
TR200102959T2 (tr) * 1999-04-12 2002-04-22 Aventis Pharma Limited İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri
CA2373883A1 (en) 1999-07-02 2001-01-11 Stuart A. Lipton Method of reducing neuronal injury or apoptosis
ES2218391T3 (es) 2000-03-06 2004-11-16 Smithkline Beecham Plc Derivados de imidazol como inhibidores de raf-cinasa.
EP1268432A1 (en) 2000-03-24 2003-01-02 Millenium Pharmaceuticals, Inc. ISOQUINOLONE INHIBITORS OF FACTOR Xa
US6548517B2 (en) 2000-03-24 2003-04-15 Millennium Pharmaceuticals, Inc. Oxindole inhibitors of factor Xa
JP2001322903A (ja) 2000-05-15 2001-11-20 Kumiai Chem Ind Co Ltd 農園芸用殺菌剤組成物
AU2001278045B2 (en) * 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6756410B2 (en) * 2000-08-30 2004-06-29 Kamal D. Mehta Induction of LDL receptor expression by extracellular-signal regulated kinase, ERK-1/2
JP4734705B2 (ja) 2000-10-31 2011-07-27 三菱化学株式会社 リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
DE10060292A1 (de) * 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament
SI1341769T1 (sl) * 2000-12-15 2008-02-29 Vertex Pharma Inhibitorji bakterijske giraze in njihove uporabe
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
CA2435820A1 (en) * 2001-02-08 2002-08-15 Karo Bio Ab Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
JP2004525140A (ja) * 2001-03-26 2004-08-19 ユニサーチ リミテッド ガンの治療方法及び該治療方法に使用する組成物
JP4073786B2 (ja) 2001-04-16 2008-04-09 田辺三菱製薬株式会社 高コンダクタンス型カルシウム感受性ｋチャネル開口薬
US6855714B2 (en) * 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
WO2003024899A2 (en) 2001-09-17 2003-03-27 Bristol-Myers Squibb Company CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
EP1434579B1 (en) * 2001-10-09 2011-06-08 Amgen Inc. Imidazole derivatives as antiinflammatory agents
US7039413B2 (en) * 2001-10-24 2006-05-02 Ntt Docomo, Inc. Mobile station transfer control system, cell transfer control method, mobile station, cell transfer control method at mobile station, cell transfer control program, control apparatus, and allocating method of communication resources
TW200300140A (en) 2001-11-14 2003-05-16 Novartis Ag Organic compounds
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
JP4136395B2 (ja) 2002-02-22 2008-08-20 クミアイ化学工業株式会社 農園芸用殺菌剤組成物
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
DE60329910D1 (de) 2002-03-29 2009-12-17 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
CN100360521C (zh) 2002-04-25 2008-01-09 帝人株式会社 具有ccr3拮抗作用的4,4-二取代的哌啶衍生物
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
TWI341314B (en) 2002-08-09 2011-05-01 Astrazeneca Ab New compounds
ES2325687T3 (es) * 2002-09-18 2009-09-14 Pfizer Products Inc. Compuestos de imidazol novedosos como inhibidores del factor de crecimiento transformante (tgf).
AU2003271548A1 (en) 2002-10-13 2004-05-04 Neurosearch A/S Use of skca channel blocking drugs for combating parkinson's disease
WO2004035740A2 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
US20050054705A1 (en) * 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
WO2004103995A1 (en) 2003-05-20 2004-12-02 Novartis Ag N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
WO2005000404A2 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
CA2531418A1 (en) 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
EP1654251A4 (en) 2003-08-14 2009-03-11 Smithkline Beecham Corp CHEMICAL COMPOUNDS
SI2392564T1 (sl) 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
PT1682126E (pt) * 2003-10-16 2009-10-02 Novartis Vaccines & Diagnostic Benzazois substituídos e sua utilização como inibidores da quinase raf
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
PL2046292T3 (pl) * 2006-07-21 2010-08-31 Novartis Ag Preparaty eterów benzymidazolilo-pirydylowych

Also Published As

Publication number Publication date
CA2619966A1 (en) 2007-03-08
CY1112157T1 (el) 2015-12-09
IL189080A (en) 2013-05-30
PT1924577E (pt) 2011-07-04
SI1924577T1 (sl) 2011-07-29
GEP20105004B (en) 2010-06-10
MA29772B1 (fr) 2008-09-01
CY1111871T1 (el) 2015-11-04
TNSN08089A1 (en) 2009-07-14
AU2006287688B2 (en) 2010-08-19
US8592459B2 (en) 2013-11-26
US20080287682A1 (en) 2008-11-20
IL189194A (en) 2013-09-30
JP2009507794A (ja) 2009-02-26
EP1924577B1 (en) 2011-03-30
DK1926722T3 (da) 2011-12-19
GT200600394A (es) 2008-03-17
US7767820B2 (en) 2010-08-03
KR20080039965A (ko) 2008-05-07
AU2006284666A1 (en) 2007-03-08
NI200800060A (es) 2009-03-03
PL1926722T3 (pl) 2012-02-29
ATE526325T1 (de) 2011-10-15
WO2007030377A1 (en) 2007-03-15
WO2007027950A1 (en) 2007-03-08
JP2009507026A (ja) 2009-02-19
JP2013060458A (ja) 2013-04-04
EP1926722B1 (en) 2011-09-28
HK1117519A1 (en) 2009-01-16
SMP200800022B (it) 2008-04-02
RS52099B (en) 2012-06-30
EA200800441A1 (ru) 2008-08-29
HN2008000317A (es) 2011-02-16
JP5210866B2 (ja) 2013-06-12
ECSP088210A (es) 2008-03-26
TWI387592B (zh) 2013-03-01
TNSN08088A1 (en) 2009-07-14
PE20070335A1 (es) 2007-04-21
AU2006287688A1 (en) 2007-03-15
MA29915B1 (fr) 2008-11-03
BRPI0615309A2 (pt) 2011-05-17
US20100234394A1 (en) 2010-09-16
EP1926722A1 (en) 2008-06-04
DE602006021036D1 (de) 2011-05-12
US20070049622A1 (en) 2007-03-01
HRP20110312T1 (hr) 2011-08-31
JP2013060457A (ja) 2013-04-04
JP5210867B2 (ja) 2013-06-12
PT1926722E (pt) 2012-01-11
TW200804346A (en) 2008-01-16
US20070161680A1 (en) 2007-07-12
SMAP200800022A (it) 2008-04-02
CR9716A (es) 2008-04-16
SI1926722T1 (sl) 2012-01-31
PL1924577T3 (pl) 2011-09-30
US20100256375A1 (en) 2010-10-07
NZ565451A (en) 2011-05-27
TW200804345A (en) 2008-01-16
KR20080039964A (ko) 2008-05-07
BRPI0615309B1 (pt) 2021-07-27
US7732465B2 (en) 2010-06-08
ECSP088218A (es) 2008-03-26
MY163886A (en) 2017-11-15
IL189080A0 (en) 2008-08-07
CA2620472C (en) 2013-12-24
DK1924577T3 (da) 2011-05-16
IL189194A0 (en) 2008-06-05
ATE503751T1 (de) 2011-04-15
EP1924577A1 (en) 2008-05-28
US20090170904A1 (en) 2009-07-02
HRP20110939T1 (hr) 2012-01-31
ES2374451T3 (es) 2012-02-16
BRPI0615314A2 (pt) 2011-05-17
PE20070427A1 (es) 2007-04-21
US7482367B2 (en) 2009-01-27
CA2620472A1 (en) 2007-03-15
HK1117523A1 (en) 2009-01-16
AR055622A1 (es) 2007-08-29
MY148694A (en) 2013-05-31
AR057109A1 (es) 2007-11-14
NZ565450A (en) 2011-04-29
AU2006284666B2 (en) 2011-04-28
CU23784B7 (es) 2012-02-15
CU20080027A7 (es) 2010-12-08
EA014230B1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
NO20081476L (no) Substituerte benzimidazoler og fremgangsmater for fremstilling
NO20090246L (no) Substituerte isoindoler som bace-inhibitorer og deres anvendelse
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
TW201129555A (en) Process for the manufacture of dabigatrane etexilate
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
PE20141191A1 (es) Compuestos como inhibidores de bace
NO20082598L (no) ERBB-inhibitorer
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20075626L (no) Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
NO20075406L (no) Pyrimidindionerivater som prokineticin-2-reseprorantagonister
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
EA200901039A1 (ru) Способ получения производного бензимидазола
TW200738692A (en) New substituted glycinamides, process for their manufacture and use thereof as medicaments
NO20083390L (no) Piperaziner og piperidiner som mGluR5-forsterkere
NO20093200L (no) Tiazolidinderivater
NO20084530L (no) Substituerte prolinamider, deres produksjon og anvendelse som medikament
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
NO20082629L (no) Macrocyklisk factor VIIa-inhibitorer anvendbare som antikoagulanter
NO20082096L (no) Azaindol-2-karboksamidderivativer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application